DexCom, Inc.
DXCM
Rangering i aksjer
#758
DexCom, Inc. is a medical technology company primarily focused on innovating,... DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Aksjekurs
$85.72
Sist synkronisert: 2026-10-20
Markedsverdi
$32.35B
Endring (1 dag)
-0.30%
Endring (1 år)
22.90%
Land
US
Handel DexCom, Inc. (DXCM)
Kategori
Healthcare
Antall utestående aksjer for DexCom, Inc. (DXCM)
Antall utestående aksjer per June 2026: 383.70M
Ifølge DexCom, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 383.70M. Ved slutten av December 2024 hadde selskapet 404.63M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for DexCom, Inc. (DXCM) fra 2000 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 383.70M | -1.67% |
| 2025 | 390.20M | -3.57% |
| 2024 | 404.63M | 4.83% |
| 2023 | 386.00M | -0.87% |
| 2022 | 389.40M | 0.65% |
| 2021 | 386.90M | 2.46% |
| 2020 | 377.60M | 3.62% |
| 2019 | 364.40M | 3.29% |
| 2018 | 352.80M | 2.20% |
| 2017 | 345.20M | 3.23% |
| 2016 | 334.40M | 4.76% |
| 2015 | 319.20M | 6.12% |
| 2014 | 300.80M | 5.77% |
| 2013 | 284.40M | 3.49% |
| 2012 | 274.80M | 4.73% |
| 2011 | 262.40M | 15.29% |
| 2010 | 227.60M | 28.31% |
| 2009 | 177.39M | 50.40% |
| 2008 | 117.95M | 4.15% |
| 2007 | 113.25M | 3.95% |
| 2006 | 108.94M | 43.77% |
| 2005 | 75.78M | 728.71% |
| 2004 | 9.14M | 5.35% |
| 2003 | 8.68M | 6.05% |
| 2002 | 8.18M | 7.89% |
| 2001 | 7.59M | 9.81% |
| 2000 | 6.91M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 1.74B | 354.27% |
US
|
|
| 1.28B | 234.14% |
IE
|
|
| 383.50M | -0.05% |
US
|
|
| 1.48B | 285.09% |
US
|
|
| - | - |
DE
|
